Nathan John Bowen

Title: Nathan John Bowen: Innovator in Ovarian Cancer Treatment

Introduction

Nathan John Bowen is a prominent inventor based in Atlanta, GA (US). He has made significant contributions to the field of cancer research, particularly in the treatment of ovarian cancer. His innovative approach focuses on utilizing the miR-200 family to induce mesenchymal-to-epithelial transition (MET) in ovarian cancer cells.

Latest Patents

Nathan John Bowen holds 1 patent related to his groundbreaking work. His patent, titled "MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells," outlines a method for treating ovarian cancer. The method involves delivering one or more miR-200 family members to a mammalian subject in need, in an effective amount to treat the cancer. Additionally, the patent provides methods for preventing metastasis and sensitizing ovarian cancer to cytotoxic therapy. It also includes techniques for reducing epithelial-to-mesenchymal transition (EMT) in ovarian cancer cells.

Career Highlights

Nathan John Bowen is affiliated with the Georgia Tech Research Corporation, where he conducts his research and development. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from ovarian cancer. His innovative methods aim to enhance the effectiveness of existing therapies and provide new avenues for cancer treatment.

Collaborations

Nathan has collaborated with notable colleagues in his field, including John Francis McDonald and LiJuan Wang. These collaborations have contributed to the advancement of research in cancer treatment and have fostered a productive environment for innovation.

Conclusion

Nathan John Bowen is a dedicated inventor whose work in ovarian cancer treatment showcases the potential of innovative therapies. His contributions to the field are paving the way for improved patient outcomes and advancing cancer research.